Category: News
-
New article online!
We have a new publication! This one relates to our work on the exposure-response relationships for efficacy and safety for mosunetuzumab, a T-cell engaging bispecific antibody targeting CD20xCD3 and approved for the treatment of relapsed/refractory follicular lymphoma. You can read it at Clinical Pharmacology and Therapeutics. Li CC, Bender B, Wilkins J, Li F, Turner…
-
